Use of positron emission tomography with [18F]-FDG in oncology: Results in gynecologic cancers;Résultats dans les cancers gynécologiques

Bulletin du Cancer

Volumn 90, Issue 2 SPEC. ISS., 2003, Pages

  Bourguet, Patrick ^a   Blanc Vincent, Marie Pierre ^b   Boneu, Andrée ^c   Bosquet, Lise ^b   Chauffert, Bruno ^d   Corone, Carine ^e   Courbon, Frédéric ^c   Devillers, Anne ^a   Foehrenbach, Hervé ^f   Lumbroso, Jean Daniel ^g   Mazselin, Philippe ^f   Montravers, Françoise ^h   Moretti, Jean Luc ⁱ   Talbot, Jean Noël ^h   Avril, Marie Françoise ^g   Banal, Alain ^e   Bey Boeglin, Martine ^j   Bonichon, Françoise ^k   Bugat, Rolland ^c   Bui Nguyen, Binh ^k   Cherel, Pascal ^e   Chevreau, Christine ^c   Fervers, Béatrice ^b   Floiras, Jean Louis ^e   Fournier, Robert ^l   Goldwasser, François ^m   Goupil, Alain ^e   Grahek, Dany ^h   Guillo, Sylvie ^b   Helal, Ourkia ⁿ   Houlgatte, Alain ^f   Lacau St Guily, Jean ^h   Lamy De La Chapelle, Thierry ^o   Pecking, Alain ^e   Périé, Sophie ^h   Reboul, François ^p   Théodore, Christine ^g   Tilly, Hervé ^q   Vaylet, Fabien ^r   Véra, Pierre ^q   Bataillard, A ^b   Bey, P ^s   Borges Paninho, H ^b   Brusco, S ^b   Carretier, J ^b   Debuiche, S ^b   Delavigne, V ^b   Esteves E ^b   Fabre, N ^b   Farsi, F ^t   Gory Delabaere, G ^b   Guy, A G ^b   Haugh, M ^b   Laforet C ^b   Leichtnam, L ^b   Luporsi, E ^u   Philip, T ^t   Renaud Salis, J L ^k   Rope D ^b   Theobald, S ^v   more..

^a CENTRE EUGÈNE MARQUIS   (France)

^b FNCLCC   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Biostatistic and Quality of Life Unit Georges François Leclerc Center   (France)

^e CENTRE RENÉ HUGUENIN   (France)

^f University of Paris Descartes   (France)

^g INSTITUT GUSTAVE ROUSSY   (France)

^h HÔPITAL TENON   (France)

ⁱ AVICENNE HOSPITAL   (France)

^j Cabinet du Docteur Fargeon   (France)

^k Intitut Bergonie   (France)

^l Military Teaching Hospital Sainte Anne   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ HÔPITAL ANTOINE BÉCLÈRE   (France)

^o PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^p INSTITUT SAINTE CATHERINE   (France)

^q CENTRE HENRI BECQUEREL   (France)

^r PERCY MILITARY HOSPITAL   (France)

^s INSTITUT CURIE   (France)

^t CENTRE LÉON BÉRARD   (France)

^u CENTRE ALEXIS VAUTRIN   (France)

^v CENTRE PAUL STRAUSS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DRUG RESPONSE; GYNECOLOGIC CANCER; HISTOLOGY; HUMAN; METASTASIS; METHODOLOGY; ONCOLOGY; OVARY CANCER; PERFORMANCE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; REVIEW; STANDARD; TREATMENT OUTCOME; UTERUS CANCER;

BREAST NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; UTERINE NEOPLASMS; VAGINAL NEOPLASMS;

EID: 17544398650     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Mauriac L, Luporsi E, Cutuli B, Garbay JR, Giard S, Spyratos F, et al. Fédération nationale des centres de lutte contre le cancer, ed. Cancers du sein infiltrants non métastatiques. Paris: John Libbey Eurotex, 2001. Standards, Options & Recommandations, vol. 12.
2. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 1993; 72: 2979-85.
3. Torizuka T, Zasadny KR, Recker B, Wahl RL. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies. Radiology 1998; 207: 767-74.
4. 18F]-FDG dans le diagnostic, le bilan d'extension et la prise en charge du cancer du sein. Imagerie fonctionnelle et métabolique 1998; 22: 515-9.
5. Jager J, Merkle E, Lang N. Erlangen tumor marker study on breast cancer. J Tumor Marker Oncol 1991; 6: 56.
6. Nicolini A, Anselmi L, Michelassi C, Carpi A. Prolonged survival by «early» salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997; 76: 1106-11.
7. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. The GIVIO Investigators [Comment in: ACP J Club. 1994; 121: 76-7]. JAMA 1994; 271: 1587-92.
8. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. National Research Council Project on Breast Cancer follow-up [Comment in: ACP J Club. 1994; 121: 76-7]. JAMA 1994; 271: 1593-7.
9. Baum RP, Niesen A, Schroder O, Adams S, Hertel A, Osterlob M, et al. A prospective evaluation of whole body FDG-PET, CT Scan and immunoscintigraphy in the detection of ovarian carcinoma reccurences. Eur J Nuclear Med 1998; 25: 942 (abstr. OS-424).
10. Shankar LK, Alavi A, Mangan C, Morgan M, Bhatnagar A, Eisenberg D, et al. The clinical role of FDG-PET in the management of residual and/or recurrent ovarian carcinoma. J Nuclear Med 1998; 39 (abstr. A-1097).
11. Garcia MJ, Crespo-Jara AA, Marti JM, Lopez G, Arbizu J, Minguez J, et al. Impact of whole body PET-FDG in the early detection or recurrent ovarian cancer. J Nuclear Med 1999; 40 (abstr. A-424).
12. Lieberman G, Hilson AJW, Buscombe JR, Adamson K, MacLean AB, Green AJ, et al. initial findings of a hybrid positron emission tomography camera system for the identification and monitoring of ovarian cancer. J Nuclear Med 1999; 40 (abstr. A-541).
13. Torizuka T, Nobezawa S, Nagashima S, Maeda M, Kanno T, Futasubashi M, et al. Role of whole body FDG-PET in management of patients with recurrent ovarian cancers. J Nuclear Med 2000; 41 (abstr. A-1318).
14. 18F-FDG Scan with dual head coincidence gamma camera. J Nuclear Med 2000; 41 (abstr. A-1316).
15. Turkalow A, Yeung HW, Macapinlac HA, Nunez RF, Sanchez AF, Larson SM. Peritoneal carcinosis: the role of FDG-PET. J Nuclear Med 2000; 41 (abstr. A-140).
16. Kim JH, Choi CW, Kim BG, Park SY, Lee ED. FDG-PET in patients with cervical cancer of uterus: experience in patients with clinically no evidence of disease. J Nuclear Med 2000; 41 (abstr. A-1309).
17. Pietrzyk U, Scheidhauer K, Scharl A, Schuster A, Schicha H. Presurgical visualization of primary breast carcinoma with PET emission and transmission imaging. J Nuclear Med 1995; 36: 1882-4.
18. Raylman RR, Fisher SJ, Brown RS, Ethier SP, Wahl RL. Fluorine-18-fluorodeoxyglucose-guided breast cancer surgery with a positron-sensitive probe: validation in preclinical studies. J Nuclear Med 1995; 36: 1869-74.
19. Weinberg I, Majewski S, Weisenberger A, Markowitz A, Aloj L, Majewski, et al. Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. Eur J Nuclear Med 1996; 23: 804-6.
20. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nuclear Medicine Communications 1996; 17: 197-8.
21. Avril N, Bense S, Ziegler SI, Dose J, Weber W, Laubenbacher C, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nuclear Med 1997; 38: 1186-91.
22. Imran MB, Kubota K, Yamada S, Fukuda H, Yamada K, Fujiwara T, et al. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. J Nuclear Med 1998; 39: 1219-23.
23. Bleckmann C, Dose J, Bohuslavizki KH, Buchert R, Klutmann S, Mester, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nuclear Med 1999; 40: 2021-4.
24. Yutani K, Tatsumi M, Shiba E, Kusuoka H, Nishimura T. Comparison of dual-head coincidence gamma camera FDG imaging with FDG PET in detection of breast cancer and axillary lymph node metastasis. J Nuclear Med 1999; 40: 1003-8.
25. Boerner AR, Weckesser M, Herzog H, Schmitz T, Audretsch W, Nitz U, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nuclear Med 1999; 26: 226-30.
26. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1991; 179: 765-70.
27. Tse NY, Hoh CK, Hawkins RA, Zinner MJ, Dahlbom M, Choi Y, et al. The application of positron emission tomographic imaging with fluoro-deoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216: 27-34.
28. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187: 743-50.
29. Nieweg OE, Kim EE, Wong WH, Broussard WF, Singletary SE, Hortobagyi, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71: 3920-5.
30. Crowe JPJ, Adler LP, Shenk RR, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol 1994; 1: 132-40.
31. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21: 280-3.
32. 18F] FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nuclear Med 1996; 23: 618-23.
33. Avril N, Dose J, Janicke F, Ziegler S, Romer W, Weber W, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Instit 1996; 88: 1204-9.
34. Palmedo H, Bender H, Grunwald F, Mallrnann P, Zamora P, Krebs D, et al. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours. Eur J Nuclear Med 1997; 24: 1138-45.
35. Noh DY, Yun IJ, Kang HS, Kim YC, Kim JS, Chung JK, et al. Detection of cancer in augmented breasts by positron emission tomography. Eur J Surg 1999; 165: 847-51.
36. Bakheet SM, Powe J, Ezzat A, Bakri Y. Incidental second primary in the breast detected by F-18 FDG positron emission tomography scan. Clin Nuclear Med 1998; 23: 616.
37. Yutani K, Shiba E, Kusuoka H, Tatsumi M, Uehara T, Taguchi T, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Computer Assisted Tomography 2000; 24: 274-80.
38. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, et al. Fluorine-18-2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nuclear Med 2001; 28: 351-8.
39. Holle LH, Trampert L, Lung-Kurt S, Villena-Heinsen CE, Puschel W, Schmidt S, et al. Investigations of breast tumors with fluorine-18-fluorodeoxyglucose and SPECT. J Nuclear Med 1996; 37: 615-22.
40. Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M, Yang DJ, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nuclear Med 1996; 37: 931-8.
41. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nuclear Med 1996; 23: 1588-93.
42. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203: 323-7.
43. Greco M, Crippa F, Agresti R, Seregni E, Getali A, Giovanazzi R, et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst 2001; 93: 630-5.
44. Smith IC, Ogston KN, Whitford P, Smith FW, Sharp P, Norton M, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228: 220-7.
45. Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonaseta TJ, Fusselman MJ, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nuclear Med 1995; 36: 1766-74.
46. 18F]-D-glucose. Cancer 1998; 82: 2227-34.
47. Bender H, Kirst J, Palmedo H, Schomburg A, Wagner U, Ruhlmann J, et al. Value of 18-fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997; 17: 1687-92.
48. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998; 16: 3375-9.
49. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nuclear Med 1998; 39: 431-5.
50. Hathaway PB, Mankoff DA, Maravilla KR, Austin-Seymour MM, Ellis GK, Gralow JR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999; 210: 807-14.
51. Ahmad A, Barrington S, Maisey M, Rubens RD. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer 1999; 79: 478-82.
52. Pecking AP, Méchélany-Corone C, Bertrand-Kermogant F, Albérini JL, Goupil A, Floiras JL, et al. Detection of occult disease in breast cancer using fluorodeoxyglucose camera based positron emission tomography. Clin Breast Cancer 2001; 2: 229-34.
53. Eubank WB, Mankoff DA, Takasugi J, Vesselle H, Eary JF, Shanley TJ, et al. 18-fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol 2001; 19: 3516-23.
54. Chaiken L, Rege S, Hoh C, Choi Y, Jabour B, Juillard G, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Intern J Radiation Oncol Biol Physics 1993; 27: 455-64.
55. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11: 2101-11.
56. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13: 1470-7.
57. 18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2: 933-9.
58. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S, Chilcott F, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18: 1676-88.
59. Schelling M, Avril N, Nahrig J, Kuhn W, Romer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18: 1689-95.
60. Buscombe JR, Cwikla JB, Thaktar DS, Hilson AJ. Scintigraphic imaging of breast cancer: a review. Nuclear Medicine Communications 1997; 18: 698-709.
61. Bombardieri E, Crippa F, Maffioli L, Draisma A, Chiti A, Agresti R, et al. Nuclear medicine approaches for detection of axillary lymph node metastases. Quarterly J Nuclear Med 1998; 42: 54-65.
62. Flanagan FL, Dehdashti F, Siegel BA. PET in breast cancer. Semin Nuclear Med 1998; 28: 290-302.
63. Greco M, Agresti R, Giovanazzi R. Impact of the diagnostic methods on the therapeutic strategies. Quarterly J Nuclear Med 1998; 42: 66-80.
64. Hoh CK, Schiepers C. 18-FDG imaging in breast cancer. Semin Nuclear Med 1999; 29: 49-56.
65. O'Doherty MJ. PET in oncology I-lung, breast, soft tissue sarcoma. Nuclear Med Communications 2000; 21: 224-9.
66. Avril N, Rose CA, Schelling M, Dose J, Kuhn W, Bense S, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18: 3495-502.
67. Wahl RL. Current status of PET in breast cancer imaging, staging, and therapy. Semin Roentgenol 2001; 36: 250-60.
68. 18F]FDG). Gynecol Oncology 1993; 51: 197-204.
69. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993; 51: 175-81.
70. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994; 53: 331-8.
71. Bohdiewicz PJ, Scott GC, Juni JE, Fink-Bennett D, Wilner F, Nagle C, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: early observations. Clin Nuclear Med 1995; 20: 230-6.
72. Yuan CC, Liu RS, Wang PH, Ng HT, Yeh SH. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma: initial report. J Reprod Med 1999; 44: 775-8.
73. Wang PH, Liu RS, Li YF, Ng HT, Yuan CC. Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent primary serous peritoneal carcinoma: an initial report. Gynecol Oncol 2000; 77: 44-7.
74. Grab D, Flock F, Stohr I, Nussle K, Rieber A, Fenchel S, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncology 2000; 77: 454-9.
75. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000; 10: 761-7.
76. Pecking AP, Méchéléany-Corone C, Albérini JL, Bertrand-Kermogant F, Pallud C, Pichon MF. La tomographie d'émission par positons au 18-fluorodéoxyglucose (TEP-FDG) dans les cancers épithéliaux de l'ovaire. Oncologie 2001; 3: 145-9.
77. Sugawara Y, Eisbruch A, Kosuda S, Reeker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nuclear Med 1999; 40: 1125-31.
78. 18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer. Oncology Reports 2000; 7: 1261-4.
79. Umesaki N, Tanaka T, Miyama M, Kawamura N, Ogita S, Kawabe J, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001; 80: 372-7.
80. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17: 41-5.
81. Kerr IG, Manji MF, Powe J, Bakheet S, Al Suhaibani H, Subhi J. Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol Oncol 2001; 81: 477-80.
82. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001; 19: 3745-9.
83. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, Ihling C, Hogetle S, Mix M, et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001; 218: 776-82.
84. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Intern J Gynecol Cancer 2001; 11: 263-71.